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Present in numerous tissues, mesenchymal stem cells/multipotent stromal cells (MSCs) can diﬀerentiate into diﬀerent cell types
from a mesoderm origin. Their potential has been extended to pluripotency, by their possibility of diﬀerentiating into tissues and
cells of nonmesodermic origin. Through the release of cytokines, growth factors and biologically active molecules, MSCs exert
important paracrine eﬀects during tissue repair and inﬂammation. Moreover, MSCs have immunosuppressive properties related
to non-HLA restricted immunosuppressive capacities. All these features lead to an increasing range of possible applications of
MSCs, from treating immunological diseases to tissue and organ repair, that should be tested in phase I and II clinical trials. The
mostwidely usedMSCsare culturedfrom bonemarrowor adipose tissue.For clinical trialimplementation, BM MSCsandADSCs
should be produced according to Good Manufacturing Practices. Safety remains the major concern and must be ensured during
culture and validated with relevant controls. We describe some applications of MSCs in clinical trials.
1.Introduction
From the end of the 1960s to the beginning of the 1970s,
a Soviet scientist, Alexander Friedenstein, discovered a
population of adherent cells in bone marrow (BM) that
could diﬀerentiate into osteoblasts, chondrocytes, and
hematopoietic stromal supportive cells [1]. The cells had
a ﬁbroblast shape, and when seeded at low density, some
could form clonal colonies, which suggested the presence
of precursor cells, the colony-forming unit-ﬁbroblasts.
B e c a u s et h ec e l l sw e r ec a p a b l eo fd i ﬀerentiating into various
lineages of the mesoderm, they were named mesenchymal
stem cells (MSCs) [2]. The stemness status and particularly
the long-term self-renewal potential of MSCs has not been
deﬁnitely established, so the preferred term is multipotent
mesenchymal stromal cells [3], both terms being abbreviated
to MSCs. In general, MSCs refer to native stem cells present
in vivo in BM and to derived cultured cells.
Cultured MSCs are a mix of cells ranging from progen-
itors to mature stromal cells. Besides their diﬀerentiation
potential, MSCs have an immunosuppressive eﬀect both in
vitro and in vivo by acting on all immune eﬀectors [4].
However, the role of MSCs in tissue repair is not restricted to
their diﬀerentiation potential or immunosuppressive eﬀects.
Indeed,MSCshaveconsistenttrophiceﬀectsmediatedbythe
wide range of growth factors and cytokines they produce [5].
These biological properties of MSCs rapidly led to
investigation of their use in cell-based therapy by the middle
of the 1990s. Caplan’s team was the ﬁrst to intravenously
inject autologous, cultured MSCs in patients during a safety
assessment trial [6]; up to 50 × 106 MSCs could be safely
injected in humans. Later, injected MSCs were used in
clinical trials to treat diseases such as osteogenesis imperfecta
[7], metachromatic leukodystrophy [8], acute myocardial
infarction [9], and graft-versus-host disease (GVHD) [10].
MSCs were also implanted to treat bone defects [11, 12].2 Stem Cells International
More than 50 clinical trials related to MSCs have been
reported at http://www.clinicaltrials.gov.
MSC populations with similar properties are found in
almost all tissues in mammals and humans [13, 14]. Among
them, adipose tissue is the most promising source of MSC-
like cells suitable for clinical trials. Indeed, since the descrip-
tion of adipose-derived stromal cells (ADSCs) by Zuk and
colleagues, in 2001, the large amount of data generated has
shownadiposetissuetobetherichestsourceofmesenchymal
progenitorcells(ADSCsareatleast100timesmoreabundant
in adipose tissue than are MSCs in BM). ADSCs and MSCs
sharemanycharacteristics[15]butalsodiﬀerencesinprotein
and function [16]( Table 1). For example, ADSCs have
greaterangiogenicpotentialthandoMSCs[17].ADSCswere
used in clinical trials as soon as 5 years after their description
[18,19]andmorethan10clinicaltrialshavebeenreportedat
http://www.clinicaltrials.gov. The clinical use of MSCs from
other sources, especially the fetus, is far less advanced.
In this paper, we report on the current experience in
the use of MSCs and ADSCs. First we discuss culture
requirements and safety concerns, and then describe several
ongoing clinical trials.
2. CultureRequirements:
From Bench to Bedside
2.1. Culture Medium. The proof of concept and original data
obtained in vitro and in vivo in the ﬁeld of cell therapy are
generally acquired with cells derived from culture protocols
established for research use and do not necessarily follow
Good Manufacturing Practices (GMP) rules. Thus, before
injecting cells in humans, the ﬁrst step is to replace research
reagents with products suitable for human use. At this
step, the two main problems are to accurately adapt the
culture protocol with appropriate reagents and to prove that
the resulting human cell culture exhibits all the properties
described in the proof of concept.
No well-established rule exists to adapt the culture
protocol, but the adaptation must be progressive (change
one parameter at a time), with a careful validation of the
therapeutic properties of the cells at each step. Because
animal experiments must be sparingly used (referred to
the 3R statement of the European Community: reduce
replace reﬁne), in vitro validation tests must be preferred
and developed in order to limit animal experimentation.
For example, angiogenic properties can be estimated by the
dosage of angiogenic factors released in the culture medium
and/or by measurement of in vitro vessel-like structure
formation. Whatever the tests, they must be closely related
to the expected in vivo eﬀects of the cells. At the end of the
adaptation phase, the cell product must be tested in vivo in
small-animal models and, if possible, large-animal models.
We discuss later the relevance and validity of the animal
model.
Special attention should be paid to the risk of infectious
disease transmission to humans by components in the
culture medium. Consideration of this risk must also include
the new variant of Creutzfeld-Jakob disease. Moreover, by
using a culture medium containing proteins from an animal
origin, MSCs may retain in their cytoplasm a substantial
amount of xenogenic proteins. A standard preparation can
represent 7 to 30mg of fetal calf serum (FCS) proteins
per 100 × 106 MSCs [20]. This level of proteins may
elicit immunologic responses in vivo that could explain
some of the failures in MSC cell therapy [7, 20]. Such
data led to an eﬀort to decrease or eliminate the use of
xenogeneic components in the culture media for clinical
MSC preparations. Replacing FCS with human autologous
or AB serum has been proposed, but both appear to be less
eﬀective than FCS. However, supplementing the medium
with human AB serum and ﬁbroblast growth factor 2
can overcome this deﬁcit [21]. Alternatively, FCS can be
replaced with human plasma enriched with growth factors
contained in platelets, such as platelet-derived growth factor,
endothelial growth factor, and vascular endothelial growth
factor. These cytokines are strongly mitogenic for MSCs and
havebeenusedsincethe1980s[22,23].Theycanbeobtained
by activation of platelets with thrombin or simply by a cycle
of freezing/thawing of the plasma that disrupts the platelets
and releases growth factors [24, 25]. In our experience, this
substitute for FCS is eﬀective for MSC and ADSC expansion
in vitro: it reduces the cell doubling time by at least 30% and
the cells retain their morphology and functions.
The need to cultivate MSCs in a deﬁned medium is
important for homogeneity between cell production pro-
cesses. In the 1990s, at least two teams described formula-
tions allowing for cultivation of MSCs in a deﬁned medium
[26, 27]. Since then, some companies have developed similar
deﬁned media for MSC culture that unfortunately do not
containmoleculesinducingMSCadhesion.Thus,theculture
process requires treatment to adsorb an attachment protein
(ﬁbronectin, collagen) on the culture surface. In addition,
the formulation often is not disclosed, which prevents its
use in clinical trials. Furthermore, these formulations do not
include growth factors, which must be added to the medium,
with the concern that they have not been produced with
GMP. The following describes the culture of MSCs.
2.2. Culture Device: Closed Systems, a First Approach. The
production of MSCs, which are adherent with contact
inhibition requires substantial culture surfaces. As soon as
the clinical trial requires more than 108 MSCs, surface areas
ofcultureexceeding2000cm2areneeded,whichcorresponds
to at least seven 300-cm2 culture ﬂasks; these are time
consuming to handle and imply a nonnegligible risk of
contamination. When a large number of cells are required,
for example, for treating GVHD ([3 to 8] × 108 MSCs
per patient), the ﬂask solution will become unmanageable
because the required surface area exceeds 6000cm2.W i t h
some culture containers, reaching this surface area with a
few units is impossible. Possible solutions are the CellStacks
(Corning, the USA) and CellFactory (Nunc, Denmark)
systems, which start from a unit surface area of 635cm2
and oﬀer the possibility of 2, 5, 10, and 40 stages per
container. These devices can also be connected by tubes
for performing various operations (e.g., culture initiation,
medium exchange, cell harvesting) in a simple and protected
way. In this case, all ﬂuids must be contained in a form thatStem Cells International 3
Table 1: Features of bone-marrow derived mesenchymal stem cells (MSCs) and adipose-derived stem cells (ADSCs).
Feature MSCs ADSCs
Tissue sampling Adult Adult
General anesthesia Local anesthesia
Cell puriﬁcation process No proteolytic digestion Proteolytic digestion, generate diﬀerent cell
subsets
Phenotype CD49a, CD73, CD90, CD105 CD271 and negative
for CD34
CD49a, CD73, CD90, CD105 (CD271?) and
CD34 in early passage
Frequency (CFU-Fs) 0.005 0.05
Potency
Hematopoietic support Classic mesenchymal
lineage (adipo-, chondro- and osteogenesis)
Immunosuppressive properties Precommitted
towards osteogenesis (cultured MSCs)
Hematopoietic support Classic mesenchymal
lineage (adipo-, chondro- and osteogenesis)
Immunosuppressive properties Precommitted
towards adipogenesis Good angiogenic potential
CFU-F: colony-forming unit-ﬁbroblasts.
ensures simple handling (sterile bags with suitable connec-
tions). We have partnered with a pharmaceutical company
(MacoPharma, France) to develop a simple connection
system in which the basic medium is prepared in sterile bags
(Figures 1, 2,a n d3). This system, adapted for 2- or 5-stage
containers, ensures easy and rapid manipulation. Ten-stage
containers and the associated ﬂuid bags are so huge that
they are cumbersome for a single technician to manage. All
these systems that require connection steps cannot be strictly
assimilated into a real closed system: they must always be
handled in a very clean environment (class B zone) under a
classAﬂowhood.Abioreactorthatautomatesallthestepsof
the culture and allows for a real closed system can overcome
these limitations. Sucha machine must be versatile and allow
for the elimination of unwanted nonadherent cells, as well as
medium exchange and cell removal.
2.3.SafetyRequirements:TheRiskofTransformation. Regard-
ing safety, the risk of transformation of MSCs during the
culture process remains a major concern. Since the ﬁrst
report of spontaneous transformation of adipose-derived
human MSCs, in 2005 [28], another team reported the
same events with human BM MSCs [29]. In the ﬁrst study,
the transformation process required a long culture time
and seemed to involve a mesenchymal-epithelial transition
[30]. Concerning the second study of human BM MSC
transformation, surprisingly, the process seemed shorter,
with high frequency of transformation. However, for the ﬁrst
report, all the data concerning the transformation were later
found to be related to contamination by an epithelial cancer
cell line during the experimental procedures [31]. A similar
retraction is under publication for the second report [32].
During the same time, using diﬀerent techniques of con-
trols, karyotype, and comparative genomic hybridization,
numerous teams reported on genetically stable MSCs during
culture [33, 34]. Moreover, in France, we used two diﬀerent
clinical-grade culture protocols, with aneuploidy features in
a few productions, in two diﬀerent clinical trials to study
the signiﬁcance of these features. We used karyotype and
ﬂuorescent in situ hybridization but also looked deeper at
the molecular mechanisms involved in senescence and trans-
formation. Clinical-grade cultured human BM MSCs, with
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Figure 1: Set of tubing plus medium bag for cell seeding operation.
or without aneuploidy, did not have any selective advantage,
did not transform in culture and reached senescence with
the normal evolution of adult cells [35]. In addition, tumors
did not develop in immunocompromised mice injected with
these MSCs. Finally, we demonstrated that the BM MSCs
were not prone to genetic instability and did not easily
transform during the normal culture process. These data
andtheretractionsdescribedpreviouslystronglysuggestthat
MSCs can be produced safely. However, these studies led to
an improvement in controls for a focus on more accurate,
relevant, and sensitive targets—investigating the expression
and epigenetic status of the main genes of senescence and
transformation pathways such as p53, p21, p16ink4a,h T E R T ,
and c-myc.
2.4. Animal Models. As described previously, animal models
are necessary for demonstrating safety and eﬃcacy. In
addition to causing potential lack of eﬃcacy that could be
encountered with chemical drugs (e.g., absence of the target,
diﬀerences in metabolism, pharmacokinetics), human cell-
based products elicit an immune reactive response in the
host that rejects these cells. Thus, the cells must be tested in
immunodeﬁcient animals, which means rodents and most
often mice. Nude or severe combined immunodeﬁciency
(SCID) mice have been extensively used for this purpose,4 Stem Cells International
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Figure 3: Set of tubing with waste bag for cell detachment.
but they bear residual immune cells that could interfere
with the human cells and thus bias the results. Thus, NOG
mice or other very immunocompromised mice must be
used, although the cost and diﬃculty of the experiments
increase. Immunocompromised mice represent an aberrant
immune context for many applications of cell-based therapy.
Furthermore, the mouse may not be a relevant pathological
modelwiththeirreducedlifespanascomparedwithhumans
and their size, which leads to diﬃcult functional evaluation.
For example, the heart rate in mice is about 300/s but only
80/s in humans; thus, intramyocardial injections may be
problematic. Another solution could be to use a large-animal
model and inject animal cells produced according to the
same conditions as for human cells. Again, this solution
is not completely satisfactory because of the real “active
compound” (i.e., human cells are not tested, which implies a
speciﬁc-cellproduction protocol because animal cells cannot
be produced in the same rooms where human cells are
produced). Despite these limitations, regulatory agencies
require such validations. Thus, the validation experiments
must be a compromise agreed upon by these authorities and
must be diﬀerent and speciﬁc to the treated condition.
3.ClinicalTrialswithMSCs andADSCs
3.1. Acute Graft-Versus-Host Disease (aGVHD). Because of
the great immunomodulatory eﬀects of MSCs in vivo and
in vitro and since the ﬁrst report by Le Blanc et al. [36],
MSCs have been mainly used for treating or preventing
aGVHD during allogeneic hematopoietic stem cell (HSC)
transplantation. The eﬃciency of such therapy is greatest in
liver and gut GVHD and in children [10, 37]. Some studies
have suggested that cotransplantation of MSCs with HSCs
canreducetheincidenceofaGVHD[38].In2007,theSoci´ et´ e
Franc ¸aisedeGreﬀed eM o e l l ee tT h´ erapie Cellulaire (SFGM-
TC) started a phase II, randomized placebo-controlled
trial of corticosteroid-resistant aGVHD in patients receiving
allogeneic HSC transplantation with or without coinjection
of BM MSCs. MSCs were cultured according to a process
developed by the SFGM-TC and validated by the French
regulatory authority (AFSSaPS). The trial planned to enroll
78 patients. At month 5 and after two cell productions,
karyotype analysis revealed clones with aneuploidy features
not related to transformation [35], which led to suspension
of the trial. Before the trial suspension, 11 patients were
enrolled. This low number of patients did not allow for
analysis of eﬃcacy, but no enrolled patients receiving the
cultured MSCs showed deleterious eﬀects, even the one who
receivedMSCswithaneuploidy.Potentiallateadverseevents,
including tumors, were never demonstrated. These obser-
vations are consistent with the lack of adverse side eﬀects
(transformation of MSCs, allosensitization by mismatched
MSCs, increased incidence of infections) reported elsewhere
during or immediately after infusion of MSCs [10, 38].
Further studies addressing use of MSCs with a ran-
domized, large cohort of patients are under way [39]. Of
note,treatingaGVHDwithMSCsforanimmunosuppressive
eﬀect could lead to an increased frequency of relapse [40].
MSCs could be an eﬃcient and safe way to treat and prevent
aGVHD, but new studies should be implemented to focus on
patients at risk for grade 2 to 4 aGVHD and for patients with
visceral organ involvement.
3.2.HeartFailure. Cardiacfailureaftermyocardialinfarction
represents poor prognosis and is associated with increased
morbidityandmortality.Treatmentsforcardiacinsuﬃciency
have evolved well in recent years, but their purpose is to
improve symptoms and prevent aggravation of the disease.
Without possibility of revascularization of the myocardium,
other therapies must be considered, such as injection of
MSCs. The hope is to regenerate the cardiac muscle orStem Cells International 5
to limit the ventricular remodeling by alternative mecha-
nisms that call on the paracrine release of growth factors.
Both small- and large-animal models have demonstrated
the usefulness of MSC injection after acute and chronic
myocardial infarction [41, 42]. Although many clinical trials
have used uncultured BM cells, results of at least two clinical
trials involving MSCs have been reported. In the ﬁrst, a
Chinese team harvested BM 8 days after the myocardial
infarction, cultured it for 10 days, then reinjected the cells
intracoronarily [43]. No side eﬀects were observed, and the
cardiacwallvelocityandleftventricleejectionfractionvalues
(LVEF)wereimprovedinthetreatedgroupascomparedwith
a control group. In the second randomized, double-blind,
placebo-controlled clinical trial of 60 patients, 39 received
cryopreserved allogeneic MSCs injected intravenously 1 to
10 days after myocardial infarction [44], with no adverse
events or ectopic tissue formation observed. The group
receiving MSCs showed signiﬁcantly less arrhythmia. The
LVEF was signiﬁcantly improved in the subgroup with
anterior myocardial infarction.
Becausetheriskofcardiacfailureishighaftermyocardial
infarction, we have begun a phase I clinical trial to evaluate
the feasibility and safety of intramyocardial injection of BM
MSCs in patients with ischemic cardiopathy. We include
patients with myocardial infarction and stable symptomatic
cardiac insuﬃciency (LVEF < 45%) of ischemic origin,
without possibility of revascularization. From these patients,
we harvest 15ml BM, from which MSCs are selected by
adherence to plastic and are ampliﬁed in culture during
17 days. The culture is done in devices that allow all steps
to be performed in a near-closed system (see following
discussion). The MSCs are injected (6 × 107 MSCs) in the
border zone of the infarction location. The main outcome
of the trial is feasibility and safety of MSC intramyocardial
injection at 1 month. The secondary outcomes are clinical,
biological, and morphological eﬀectiveness during 2-year
follow-up.Weaimtovalidate,fortheﬁrsttime,thefeasibility
and safety of intramyocardial injection of MSCs to improve
the contractile function of the left ventricle and decrease
morbidityofpatientswithcardiacinsuﬃciency.Twopatients
have received the cells and have shown no adverse events.
3.3. Limb Ischemia. Critical limb ischemia (CLI) is a
peripheral arterial disease with diﬀerent grades described by
Fontaine. Grades III and IV are characterized by chronic,
ischemic pain at rest and ischemic skin lesions, either ulcers
or gangrene. This clinical diagnosis can be conﬁrmed by
hemodynamic parameters such as ankle or toe systolic
pressure. The frequency is around 32.5‰ before 40 years
of age and 71‰ above 50 years. The estimated annual
incidence of CLI ranges from 500 new cases per million
in the European Union to 1000 per million in the United
States, with diabetes being the greatest risk factor. About
60% of patients should undergo revascularization whenever
technicallypossibletopreventlimbloss.Theamputationrate
for patients is about 20%. Because of the ineﬃciency of ther-
apeutics when revascularisation is not possible, additional
limb-saving strategies, including cell therapy, are required
[45].
Results of a single clinical trial of CLI involving autolo-
gous BM mononuclear cells have been published. In total,
46 patients received intramuscular injections of (0.9 to
2.8) × 109 BM mononuclear cells retrieved from patients
under general anesthesia. The results were encouraging: 70%
of patients showed improved oxygen tension, a signiﬁcant
decrease in pain and increased mobility [46]. Half of the
patients reported no pain. The ﬁrst positive eﬀects appeared
as soon as week 4, with stabilization at 6 months after treat-
ment. Follow-up revealed signiﬁcant improvement in leg
pain, ulcer size, and pain-free walking distance maintained
during at least 2 years after the therapy, although the ankle
brachial index and transcutaneous oxygen pressure value did
not change signiﬁcantly [47].
From our preclinical data obtained from animal models,
we began a phase I monocentric clinical trial to assess
the feasibility and safety of intramuscular injections of
autologous ADSCs for patients with CLI of the leg with
no possibility of revascularization. We aimed to investigate
the possibility of preventing amputation and more largely,
decreasing morbidity. With patients under local anaesthesia,
30g of adipose tissue is sampled by liposuction. After
digestion and centrifugation of samples to separate mature,
ﬂoating adipocytes from stromal cells, ADSCs are selected by
adherence to plastic and are ampliﬁed in culture in a near-
closed system for 2 weeks. The ADSC are injected (108 cells)
intramuscularly at 45 points in all the muscles of the leg by
use of a grid.
The main outcome is feasibility and safety as assessed
by observations of local necrosis, thrombosis, local and
general infection or inﬂammation up to month 6 after ADSC
injections. The secondary outcomes are wound healing, lack
of amputation, oxygen tension at the toe or ankle, and pain.
Thetrialaimstovalidate,fortheﬁrsttime, thefeasibilityand
safety of the intramuscular injection of ADSCs to improve
vascularity in the leg. Three patients have received ADSC
injections and have shown no serious adverse events. This
trial needs to include 6 more patients.
4. FutureDirections
4.1. Allogeny. MSCs are well known to have an inhibitory
eﬀect on immune cell proliferation in vitro and in vivo [48,
49]. This observation has opened new perspectives concern-
ingtheuseofMSCsinthecontextofallogenicity,forcreating
cell banks and for treating disease when there is no time to
purify and expand cells. The results obtained with allogeneic
cells are similar to those obtained with autologous cells. For
the heart, intramyocardial injections and systemic delivery
of allogeneic MSCs have been found to preserve myocardial
viability and improve local and global heart function in
rodents and pigs [50–52]. This ﬁnding is associated with
decreased scar size and ﬁbrosis and increased angiogenesis
[53]. Most of the eﬀects seem to be due to paracrine activity
[44] and modulation of proinﬂammatory, proangiogenic,
and immunomodulatory molecules by the peri-infarcted
myocardium [54, 55]. However, the presence of transplanted
cells and these eﬀects seem to be transient [44, 54, 55].
The immunosuppressive properties of MSCs were also6 Stem Cells International
tested for allograft tolerance in a model of allogeneic heart
transplantation, withcontrasting results,including increased
rejection depending on cell dose and treatment [56, 57].
These opposite conclusions are confusing, and a deﬁnitive
answer in such a complex ﬁeld requires further experiments.
The immunomodulatory eﬀects of ADSCs have been
described in vitro and in vivo [58–62]. These eﬀects could
also be due to secreted factors such as transforming growth
factor beta, hepatocyte growth factor, prostoglandin E2, and
IDO [62] and in some areas, diﬀerent from MSC eﬀects.
Indeed, ADSCs inhibit immunoglobulin production but also
suppress this B-cell function to a much greater extent than
MSCs [63]. So the use of ADSCs could not be a simple
and direct translation of MSC uses and needs dedicated
experiments.
4.2. Cell Administration. Cells are transplanted most fre-
quently by intratissue delivery, but massive cell death is
frequently observed after the injection. To overcome such
limitations, alternative cell-delivery systems should be con-
sidered. One solution could be to render the cells more
resistant to the accompanied stress of the injection. For
example, we have shown that preconditioning with mela-
tonin increases the survival, paracrine activity, and eﬃciency
of MSCs when injected intraparenchymally [64]. This eﬀect
is a consequence of higher resistance to oxidative stress
and secretion of proangiogenic factors. Another promising
approach could be to engineer biological cell sheets to eﬃ-
ciently transplant MSCs by respecting host tissue structure.
This approach was successful with use of undiﬀerentiated
ADSCs in the heart [65]. After transplantation, the engrafted
sheet gradually grew to form a thick stratum that included
newly formed vessels, undiﬀerentiated cells, and a few
cardiomyocytes. Cardiac wall thinning was reversed in the
scar area and cardiac function improved.
Finally, the possibility of targeting cells to various
damagedsitesbybloodstreamdeliveryisattractiveandseems
suitable for these cells because they can be distributed to
any tissue with no clonal or extensive proliferation at their
ﬁnal destination site [66]. This route of delivery has been
investigated in the heart, and pharmacological agents can
modulate its eﬃciency [67].
5.CultureMedium
Althoughincreasingreports,includingthoseofclinicaltrials,
have established that MSCs are good candidates for cell-
based therapy, aspects of this therapy should be improved.
Regarding new therapeutic targets, central nervous system
diseases, autoimmune diseases, and lesions of the skin or
cornea, phase I and II trials should be developed. Moreover,
GMP conditions, particularly relevant safety controls and
closed systems, must be fully implemented, and phase I and
II trials should be performed with GMP-produced MSCs.
If MSCs are eﬀective with this process, phase III trials can
be implemented and cell products ﬁnally licensed. Our own
experience is consistent with this conclusion, and in the next
few years, cell therapy with MSCs or ADSCs will be validated
and can help treat a large number of diseases ranging from
nonunion fracture, to limb ischemia and heart failure, to
autoimmune diseases.
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